Why Belite Bio Stock Soared on Monday The company is now tantalizingly close to commercializing its leading drug candidate.
Top movers in Monday's pre-market session Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
3 Lesser-Known Healthcare Names With Major Upside in Store These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials Belite Bio Inc (
NASDAQ: BLTE ) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.
BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024.
BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024.
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Zynerba Pharmaceuticals, Inc. (
NASDAQ: ZYNE ) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration of up to $200 million in cash.
Why Shares of Belite Bio Soared This Week The clinical-stage biotech company bounced back from a 52-week low late last week.
